Search results
Results from the WOW.Com Content Network
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood , and increase HDL .
5467 19015 Ensembl ENSG00000112033 ENSMUSG00000002250 UniProt Q03181 P35396 RefSeq (mRNA) NM_001171818 NM_001171819 NM_001171820 NM_006238 NM_177435 NM_011145 RefSeq (protein) NP_001165289 NP_001165290 NP_001165291 NP_006229 NP_803184 NP_035275 Location (UCSC) Chr 6: 35.34 – 35.43 Mb Chr 17: 28.23 – 28.3 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Peroxisome proliferator ...
Efaproxiral is an analogue of bezafibrate [a lipid-lowering agent], developed for the treatment of depression, traumatic brain injury, ischemia, stroke, myocardial infarction, diabetes, hypoxia, sickle cell disease, hypercholesterolemia and as a radio sensitiser. [1] [2] [3] The chemical is a derivative of propanoic acid.
Replacements, Ltd., based in Greensboro, North Carolina, is the world's largest retailer of china, crystal and silverware, including both patterns still available from manufactures and discontinued patterns. The company, which began in 1981, had an inventory in 2011 of 14 million items from more than 340,000 patterns, with annual sales of $80 ...
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).
Williamson has reportedly been late for multiple practices, per NBA reporter Chris Haynes — a pattern of behavior that led the organization to suspend him.. Williamson returned to the court on ...
Discover the best free online games at AOL.com - Play board, card, casino, puzzle and many more online games while chatting with others in real-time.
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. [1]The drug had completed phase III clinical trials, [2] however in May 2006 Bristol-Myers Squibb announced that it had discontinued further development.